Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and Perrigo Company plc

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of TG Therapeutics, Inc. and Perrigo Company plc from 2014 to 2023. Perrigo, a stalwart in the industry, consistently reported SG&A expenses averaging around $1.1 billion annually, peaking at $1.27 billion in 2023. This reflects a steady growth of approximately 89% over the decade. In contrast, TG Therapeutics, a burgeoning biotech firm, exhibited a more volatile trajectory. Starting with a modest $24.5 million in 2014, their SG&A expenses surged by over 500% to $122.7 million by 2023. This stark contrast underscores the differing operational strategies and market positions of these companies. As TG Therapeutics scales its operations, its rising SG&A expenses highlight its aggressive growth strategy, while Perrigo's stable expenses reflect its established market presence.